(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Tuesday reported a decline in its third quarter net asset value, noting a depreciating US dollar against sterling and a decline in the share price of investees. Read More
(Alliance News) - Life Science REIT PLC on Wednesday said it signed an agreement to lease the second floor of its Rolling Stock Yard asset near King's Cross, London, to a life science company backed by Syncona Ltd. Read More
(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its treatment for acute lymphoblastic leukaemia. Read More
(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company. Read More
(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space. Read More
(Alliance News) - AstraZeneca PLC said it agreed to buy Neogene Therapeutics Inc for the treatment of cancer, as also noted by healthcare company Syncona Ltd on Tuesday. Read More
(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities. Read More
(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued. Read More
(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years. Read More
Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Thursday noted that its portfolio company Autolus Therapeutics PLC had widened its third quarter loss as it continued to progress its candidate pipeline. Read More
(Alliance News) - Syncona Ltd on Monday it will expand its retinal gene therapy pipeline with the acquisition of a Florida-based biotechnology company. Read More
Syncona Ltd - London-based investor in healthcare companies - Reports small quarterly net asset value rise on gain on foreign exchange. Net asset value per share at June 30 stands at 197.7 pence per share, up 1.7% from 194.4p at March 31. Read More
(Alliance News) - Syncona Ltd on Tuesday noted half-year results of its investees, Freeline Therapeutics Holdings PLC and Achilles Therapeutics PLC. Read More
(Alliance News) - Syncona Ltd on Monday said investee Freeline Therapeutics Holdings PLC has presented partial safety and efficacy data from a phase I/II dose confirmation trial for FLT180a, a gene therapy for haemophilia B. Read More
(Alliance News) - Syncona Ltd on Thursday reported a slight increase in net asset value, but a lower total return, as the value of its holdings fell due to market volatility, as the firm skipped its dividend again. Read More